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重要指标之一。Anti-HBc 在 HBV 感染早期即在血清出现，常终生持续存在，
其存在指示着个体“现症”或“既往”的 HBV 感染。在流行病学研究中，Anti-






立了一种新型双抗原夹心法 Anti-HBc ELISA 检测试剂（WT sHBcAb）。各种评
价显示，该试剂分析灵敏度达到 0.125 IU/mL，对各类临床标本（n=1879）的
总体检测灵敏度达到 99.7%(95%CI: 99.1~99.9%)，显著高于（p=0.002）雅培
Architect Anti-HBc 间接法试剂的 98.4%(95%CI: 97.5~99.0)，远高于(p<0.001)
国产主流竞争法试剂的 88.9%(95%CI: 87.0~90.7)；其总体特异性为 98.7%




















Hepatitis B virus( HBV) infection continues to be a major problem of public 
health for China as well as the World. Developing novel HBV diagnostics with 
improved performance is a crucial way for improvements of chronic hepatitis B 
managements and prevention or reversal of decompensated cirrhosis and reduction in 
the risk of HCC. Antibodies against hepatitis B core antigen (anti-HBc) is an 
important indicator for clinical diagnosis of hepatitis B virus(HBV) infection. Anti-
HBc is found in serum shortly after the appearance of hepatitis B surface antigen 
(HBsAg) in acute phase of HBV infections, usually persist lifelong, and indicates 
HBV infection independently of the phase of infection. Anti-HBc is also an important 
parameter for the estimation of total HBV prevlance in epidemiological studies, and 
may serve as a sentinel marker of unrecognized "occult" HBV infection and clinicians 
should consider investigating such patients with nucleic acid testing (NAT) for HBV. 
Anti-HBc testing is routinely used for blood screening in some countries with low 
HBV prevlance. 
Current commercial anti-HBc assays are mostly based on competitive/inhibitory 
immunoassay technology, which had unsatisfactory performance and was urgently 
needed  improving. In the study,  we developed a novel double-sandwich diagnostic 
immunoassay (WT sHBcAb) for Hepatitis B virus core antibodies using 
homogeneous purified recombinant full-length HBcAg capsids obtained from E.Coli. 
Performance evaluation experiments revealed the analytical sensitivity of the assay 
was 0.125 IU/mL. Among a total of 1879 clinical specimens, the sensitivity of WT 
sHBcAb was 99.7%(95%CI: 99.1~99.9%), while that of Architect Anti-HBc assay 
was 98.4% (95%CI: 97.5~99.0%) and that of XC HBcAb assay was 88.9%(95%CI: 
87.0~90.7%), respectively. The sensitivity of the new assay was significantly higher 
than that of Architect Anti-HBc assay (p=0.002) and XC HBcAb assay(p<0.001). The 
specificity of WT sHBcAb was 98.7%(95%CI: 97.6~99.4%), similar with that of 
Architect Anti-HBc assay (99.3%，95%CI: 98.4~99.8%, p=0.42), as well as that of 
XC HBcAb(98.6%，95%CI：97.4~99.3%, p=0.99). The new developed assay based 
on double-sandwich method improves the sensitivity of anti-HBc detection without 















and blood screening. 



















第一章   前言 .............................................................................................1 
1 乙型肝炎病毒病原学 .............................................................................................1 
1.1 乙型肝炎病毒颗粒和基因组结构 ..................................................................1 
1.2 乙型肝炎病毒编码蛋白 ..................................................................................3 
1.3  HBV 感染流行病学 ........................................................................................8 
2 乙型肝炎病毒的实验室诊断 ............................................................................... 11 
2.1  HBV 感染的免疫学诊断..............................................................................11 
2.2 HBV 感染的核酸诊断 ...................................................................................16 
3   HBV 核心抗体诊断价值及本研究的目的和意义 ...........................................16 
3.1 Anti-HBc 可作为血液安全筛查指标 ............................................................16 
3.2  Anti-HBc 单独阳性可作为隐匿性 HBV 感染的筛查指标 .........................17 
3.3 本研究的目的与意义.....................................................................................19 
第二章 材料和方法 .................................................................................20 




2 方法 .......................................................................................................................27 
2.1 分子克隆操作.................................................................................................27 
2.2 重组蛋白的表达、纯化及鉴定.....................................................................31 
2.3 酶联免疫吸附法（ELISA）及化学发光酶联免疫分析（CLEIA） .........35 
2.4 单抗的制备.....................................................................................................37 
2.5  统计学分析....................................................................................................39 















1.重组 HBcAg 类病毒颗粒抗原的制备.................................................................40 
1.1 C 型及 D 型 HBcAg 全长基因的扩增、序列测定及密码子改造 ..............40 
1.2 原核表达质粒 PTO-T7-CpC/CpD 的构建 ....................................................42 
1.3 PTO-T7-CpC/CpD 重组蛋白的表达 .............................................................43 
1.4 CpC/CpD 重组蛋白的体外颗粒组装............................................................45 
2. 双抗原夹心法 Anti-HBc ELISA 检测试剂的研究...........................................47 
2.1 标记抗原和包被抗原的选择.........................................................................47 
2.2 佳包被浓度和 佳标记物使用浓度的确定.............................................48 
2.3 双抗原夹心法 Anti-HBc 试剂的小试生产 ...................................................51 
2.4 双抗原夹心法 Anti-HBc 试剂的分析性能评估 ...........................................51 





第四章 讨论 .............................................................................................67 
4.1  重组全长 HBcAg 类病毒颗粒抗原的制备 .................................................67 
4.2  Anti-HBc 检测的方法学 ...............................................................................68 
4.3  Anti-HBc 和 Anti-HBe 的特异性区分..........................................................69 
4.4  Anti-HBc 的确认方法 ...................................................................................70 

















Table of contents 
VI 
Table of Contents 
Chapter 1: Abtract....................................................................................1 
1 The biological properties of Hepatitis B Virus ...........................................1 
1.1 HBV particle and genome ............................................................................1 
1.2 HBV proteins ..................................................................................................3 
1.3 The epidemiology of HBV.............................................................................8 
2  Laboratary diagnosis of HBV....................................................................... 11 
2.1 Immunological diagnosis of HBV infection ..............................................11 
2.2 Nucleic acid diagnosis of HBV infection ..................................................16 
3 Diagnosis value of Anti-HBc and content of this research...................16 
3.1 Anti-HBc can be used as a new index to screen blood .........................16 
3.2 Anti-HBc can be used as a  rough screening index in  OBI ......................17 
3.3 The content of our research.......................................................................19 
Chapter 2: Materials and Methods ..................................................20 
1  Materials ............................................................................................................20 
1.2 Reagents and Supplies...............................................................................21 
1.3 Solvents and Medium .................................................................................24 
2 Methods ..............................................................................................................27 
2.1 Molecular cloning operating method ........................................................27 
2.2 The preparation of the recombinant protein ............................................31 
2.3 ELISA and CLEIA ........................................................................................35 
2.4 The preparation of MAbs ............................................................................37 
Chapter 3: Results and Analysis .....................................................40 
1 The preparation of recombinant HBV particles........................................40 
1.1  HBc gene cloning and  sequence transformation .................................40 
1.2 Establishment of  recombinant HBc plasmid...........................................42 
1.3 Purification of recombinant HBc ................................................................43 
1.4 In vitro HBc caspid assembly.....................................................................45 
2 The double antigen sandwich immunoassay for anti-HBc ...................47 
2.1 The choose of coating and labeling antigen............................................47 













Table of contents 
VII 
2.3 Small scale production of Double sandwich HBcAb kit .........................51 
2.4 Evaluation of Double sandwich antigen  HBc kit ....................................51 
3 Clinical Trial of Double sandwich antigen Anti-HBc assay ...................61 
3.1 The reference kit in the clinical evalution.................................................61 
3.2 Clinical evaluation of testing procedures .................................................62 
3.3 Evaluation of clinical results.......................................................................63 
Chapter 3: Discussion ........................................................................67 
4.1 The preparation of recombinant full-length HBcAg VLPs antigen .......67 
4.2 Anti-HBc test methodology.........................................................................68 
4.3 Specific distinction between Anti-HBc and Anti-HBe..............................69 
4.4 Verification method of Anti-HBc................................................. 70 



















第一章   前言 
乙型肝炎病毒(Hepatitis B Virus,HBV)感染是全球 重要的公共卫生问题之
一。全球约有 20 亿人曾经感染过乙肝病毒，其中 3.6 亿为慢性感染者，每年约
有 100 万人死于由 HBV 感染引起的肝硬化和原发性肝细胞癌。HBV 感染引发
的公共卫生问题在发展中国家尤为突出[1]，75%的慢性 HBV 感染发生在亚洲和
非洲。HBV 属嗜肝 DNA 病毒科，具有明显的种属及嗜肝特性，可引起急慢性
肝炎、肝硬化、原发性肝细胞癌等肝脏疾病，以及肾病综合症、肝性脑病等肝
外疾病。HBV 感染是导致原发性肝癌（HCC）的主要原因之一[2, 3] ，HCC 导致
的死亡率在所有癌症死亡率中排名第四位[4]。我国是乙肝大国，全国约有 1.2 亿
的慢性 HBV 携带者，慢性乙肝患者约 3000 万例， HBV 感染对国民健康造成
严重威胁。 
1965 年 Blumberg 等在澳洲原住民中发现乙型肝炎的病毒标志物
HBsAg[5]，大量的流行病学调查发现其与乙型肝炎有密切关系。1970 年 Dane
等鉴定了乙型肝炎病毒颗粒，阐明了乙肝病毒的表面抗原 HBsAg、核壳成分
HBcAg 和 HBeAg[6]。1975 年，血源 HBV 疫苗问世，该疫苗具有被动免疫的保
护作用。1986 年第一个重组 HBV 疫苗 Recombivax 进入市场。1991 年世界卫






















属嗜肝 DNA 病毒科(Hepadnaviridae)。嗜肝 DNA 病毒经反转录复制，与逆转
录病毒有亲缘关系。完整病毒颗粒也称 Dane 颗粒。Dane 呈球形，直径 42nm,
由 HBs 蛋白构成外膜[6]，无其他病毒外膜的球形或尖钉状突起，由多拷贝单一
HBC 蛋白形成 20 面体核壳[10]，核心颗粒直径 34nm,内含 3.0-3.2kb 部分双链
环状 DNA 和病毒编码的聚合酶[11-13]。血清中除了含有完整毒粒，还有两种外膜
蛋白颗粒，存在较多的是 17-25nm 的小球形颗粒（HBs Spheres），存在较少
的是管形颗粒（HBs Fiaments）。 
 
图 1-1   血清中乙型肝炎病毒颗粒电镜图 
Fig.1-1  Electron micrograph of  HBV Particles, HBs Fiaments, HBs Spheres 
From:Howard Thomas. Viral Hepatitis 3rd[M].BlackWell Publishing Ltd,2005:151 
 
1.1.2  HBV 基因组 
HBV Dane 颗粒内部包裹 HBV DNA 和 HBV 特异聚合酶。HBV 基因组是
3.2kb 的部分环状双链 DNA。双链的长度不对称，全长的一链与病毒 mRNA 互
补，称为负链，较短的一链则定为正链[14, 15]。正链 5’端固定，3’端位置不固
定，长度大概为负链的 50%-100%。正链与负链的 5’端互相配对，使双链保持
环状。两条 DNA 链 5’端互相配对的部分称为粘性末端，粘性末端两侧有 11 个

















图 1-2 HBV 基因组简图[17] 
Fig 1-2 Genome of Hepatitis B Virus 
 
1.2 乙型肝炎病毒编码蛋白 
HBV 负链核苷酸序列至少有 4 个开放读框（open reading frame,ORF）分
别为 S、C、P 和 X，它们分别编码包膜蛋白（PreS/S）、核心蛋白
（PreCore/Core）、聚合酶（ploymerase）及 X 蛋白（HBxAg）。 
1.3.1 外膜蛋白 




小蛋白（S）由 S 基因编码，由 226 个氨基酸组成，中蛋白(MS)由 S 及前
S2 编码，由 281 个氨基酸组成，大蛋白(LS)由 S,前 S2 区和前 S1 区基因编

















图 1-3 HBV 三种外膜蛋白的简单比较模式图 
Fig.1-3 Schematic representation of HBV envelope proteins 
 

























图 1-4 HBV 完整病毒模型以及外膜蛋白构成 
Fig.1-4  Schematic model of the HBV Dane and HBs particles  
From:Howard Thomas. Viral Hepatitis 3rd[M].BlackWell Publishing Ltd,2005:151 
 
1.3.2 HBc 核壳蛋白 
C-ORF: 分为 C 基因区和前 C 基因区，各有起始密码子，其一合成 P21 核
壳蛋白；其二合成 P25 前 C 蛋白[18, 20]。两者蛋白虽然有大部分相同序列的氨
基酸序列，但有特异的抗原表位分别诱生抗 HBc 及抗 HBe。但 HBcAg 具有高
度免疫原性，较之 HBeAg 强 100 倍。 
HBcAg 由 C-ORF 从第二个 ATG(1901nt)起始翻译到终止子（2458nt）。
HBcAg 有保守的三维结构，根据血清型不同有 183-185 个氨基酸，相对分子量
21kd 左右, 180 个 HBcAg 聚集而形成直径 27nm 的核心颗粒。HBcAg 包裹
HBV DNA，在病毒成熟过程中起到重要作用。HBcAg 羧基末端区 145-156 位
和 172-183 位的氨基酸序列，具有与细胞核特异性集合，并将与之相连的蛋白
或 DNA 转运到细胞核中的功能。 















C/C 蛋白 P25 是 HBeAg 的前体。前体氨基酸有一个 19 肽为转运 P25 进入内
质网提供信号。信号肽被信号肽酶切割后成为中间产物 P22。P22 可转运和插
入细胞膜、释放入胞浆或转运入细胞核。当 P22 在细胞腔膜中倍细胞蛋白酶解
除羧基端 33 个残基后，便形成 157 个氨基酸的 HBeAg[21]。HBeAg 的重要功
能在于它阻断细胞毒性 T 细胞对 HBcAg 相关表位的免疫活性。 
 
 
图 1-5  HBV 前 C/C 基因及其编码蛋白 
Fig.1-5  The precore/core gene and and the translation  
 
图 1-6  HBcAg 颗粒组装过程简图 
 Fig1-6  The assemble  process figure of the HBcAg particles 
 
1.3.3  P 蛋白 
P-ORF:P 基因产物 P 蛋白是基因组中编码中 大的蛋白，含 816 个氨基
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